Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerRazelle Kurzrock, Ravi Salgia, Lei Ye et al.|Journal of Clinical Oncology|2011Cited by 551
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerSamuel A. Wells, Martin Schlumberger, Jessica E. Gosnell et al.|Journal of Clinical Oncology|2010Cited by 517
The Clinical Outcome of Prospective Screening for Multiple Endocrine Neoplasia Type 2ARobert F. Gagel, Seymour Reichlin, A H Tashjian et al.|New England Journal of Medicine|1988Cited by 330
Natural History of Familial Medullary Thyroid CarcinomaKathleen Graze, Seymour Reichlin, Ira J. Spiler et al.|New England Journal of Medicine|1978Cited by 189
Adrenal medullary hyperplasia. A morphometric analysis in patients with familial medullary thyroid carcinoma.Ronald A. DeLellis, Seymour Reichlin, Hubert J. Wolfe et al.|PubMed|1976Cited by 148